Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma
Tóm tắt
Glioma, especially glioblastoma (GBM), is the most aggressive malignant brain tumor and its standard therapy is often ineffective because of temozolomide (TMZ) resistance. Reversal of the TMZ resistance might improve the prognosis of glioma patients. We previously found that interferon-α (IFN-α) and anti-epileptic drug levetiracetam (LEV) could sensitize glioma to TMZ, respectively. In this study, we further investigated the efficiency of combining of LEV and IFN-α for improving the efficacy of TMZ. We evaluated whether LEV and IFN-α could increase TMZ efficacy using colony formation assay and cell viability assay with MGMT-positive and MGMT-negative glioma cell lines in vitro. Subcutaneous xenografts and orthotopic xenografts mice models were used in vivo to observe the tumor growth and mice survival upon treatments with TMZ, TMZ + IFN-α, TMZ + LEV, or TMZ + LEV + IFN-α. The expression levels of MGMT, markers of pro-apoptotic and anti-apoptotic in tumor samples were analyzed by Western blotting. The combinational use of IFN-α, LEV, and TMZ showed the best anti-tumor activity in MGMT-positive cell lines (U138, GSC-1, U118, and T98 G). TMZ + LEV + IFN-α further obviously increased TMZ + LEV or TMZ + IFN-α efficiency in MGMT-positive cell lines, while not in negative cell lines (SKMG-4, U87, U373, and U251) in vitro, which were also observed in subcutaneous mice models (U138, GSC-1 compared to SKMG-4, U87) and orthotopic models (GSC-1) in vivo. Strikingly, the combination of LEV and IFN-α together with TMZ significantly prolonged the survival of mice with orthotopic GSC-1 glioma. Furthermore, we confirmed that the combination of LEV and IFN-α enhanced the inhibition of MGMT and the activation of apoptosis in U138 tumor on the basis of TMZ treatment. The combination use of LEV and IFN-α could be an optimal method to overcome TMZ resistance through obvious MGMT inhibition in MGMT-positive glioma.
Tài liệu tham khảo
Neckers LM (1991) Regulation of transferrin receptor expression and control of cell growth. Pathobiology 59(1):11–18. https://doi.org/10.1159/000163610
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330
Nakada M, Furuta T, Hayashi Y, Minamoto T, Hamada J (2012) The strategy for enhancing temozolomide against malignant glioma. Front Oncol 2:98. https://doi.org/10.3389/fonc.2012.00098
Fan CH, Liu WL, Cao H, Wen C, Chen L, Jiang G (2013) O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis 4:e876. https://doi.org/10.1038/cddis.2013.388
Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26(25):4189–4199. https://doi.org/10.1200/JCO.2007.11.5964
Froscher W, Kirschstein T, Rosche J (2014) Anticonvulsant therapy for brain tumour-related epilepsy. Fortschr Neurol Psychiatr 82(12):678–690. https://doi.org/10.1055/s-0034-1385475
Yuan Y, Peizhi Z, Maling G, Wu L, Yunhe M, Xiang W, Qing M, Yanhui L, Ruofei L, Jiewen L (2015) The efficacy of levetiracetam for patients with supratentorial brain tumors. J Clin Neurosci 22(8):1227–1231. https://doi.org/10.1016/j.jocn.2015.01.025
Kim YH, Kim T, Joo JD, Han JH, Kim YJ, Kim IA, Yun CH, Kim CY (2015) Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. Cancer 121(17):2926–2932. https://doi.org/10.1002/cncr.29439
Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, Konduri SD (2010) Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 12(9):917–927. https://doi.org/10.1093/neuonc/noq044
Scicchitano BM, Sorrentino S, Proietti G, Lama G, Dobrowolny G, Catizone A, Binda E, Larocca LM, Sica G (2018) Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Cancer Cell Int 18:136. https://doi.org/10.1186/s12935-018-0626-8
Coker SA, Dandamudi UB, Beelen AP, Crosby NA, Fisher JL, Obrocea M, Ernstoff MS, Lewis LD (2013) A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours. J Chemother 25(6):362–368. https://doi.org/10.1179/1973947813y.0000000102
Shen D, Guo CC, Wang J, Qiu ZK, Sai K, Yang QY, Chen YS, Chen FR, Wang J, Panasci L, Chen ZP (2015) Interferon-alpha/beta enhances temozolomide activity against MGMT-positive glioma stem-like cells. Oncol Rep 34(5):2715–2721. https://doi.org/10.3892/or.2015.4232
Natsume A, Wakabayashi T, Ishii D, Maruta H, Fujii M, Shimato S, Ito M, Yoshida J (2008) A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol 61(4):653–659. https://doi.org/10.1007/s00280-007-0520-x
Dillman RO, Wiemann M, Oldham RK, Soori G, Bury M, Hafer R, Church C, DePriest C (1995) Interferon alpha-2a and external beam radiotherapy in the initial management of patients with glioma: a pilot study of the National Biotherapy Study Group. Cancer Biother 10(4):265–271. https://doi.org/10.1089/cbr.1995.10.265
Wu QW, Zhang ZP, Wang J, Chen FR, Zhao YY, Qu Y, Chen ZP (2017) In vitro study of antitumor effect of levetiracetam combined with temozolomide in glioma cell lines. Chin J Neurosurg Dis Res 16(3):217–220
Mei X, Chen YS, Chen FR, Xi SY, Chen ZP (2017) Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging. Neuro Oncol 19(8):1109–1118. https://doi.org/10.1093/neuonc/nox016
Roos WP, Jost E, Belohlavek C, Nagel G, Fritz G, Kaina B (2011) Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-beta and valproic acid. Cancer Res 71(12):4150–4160. https://doi.org/10.1158/0008-5472.CAN-10-3498
Lee SY (2016) Temozolomide resistance in glioblastoma multiforme. Genes Dis 3(3):198–210. https://doi.org/10.1016/j.gendis.2016.04.007
Arora A, Somasundaram K (2019) Glioblastoma vs temozolomide: can the red queen race be won? Cancer Biol Ther 20(8):1083–1090. https://doi.org/10.1080/15384047.2019.1599662
Xu CM, Zhao YD, Wu CY, Li L (2019) Repurposing drugs for the treatment of glioma. Glioma 2(2):159–164. https://doi.org/10.4103/glioma.glioma_26_19
Romoli M, Mandarano M, Romozzi M, Eusebi P, Bedetti C, Nardi Cesarini E, Verzina A, Calvello C, Loreti E, Sidoni A, Giovenali P, Calabresi P, Costa C (2019) Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events. J Neurol. https://doi.org/10.1007/s00415-019-09410-0
Maschio M, Dinapoli L, Sperati F, Pace A, Fabi A, Vidiri A, Muti P (2011) Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol 104(1):205–214. https://doi.org/10.1007/s11060-010-0460-x
Cardona AF, Rojas L, Wills B, Bernal L, Ruiz-Patino A, Arrieta O, Hakim EJ, Hakim F, Mejia JA, Useche N, Bermudez S, Carranza H, Vargas C, Otero J, Mayor LC, Ortiz LD, Franco S, Ortiz C, Gil-Gil M, Balana C, Zatarain-Barron ZL (2018) Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma. J Neurooncol 136(2):363–371. https://doi.org/10.1007/s11060-017-2660-0
Du Z, Cai C, Sims M, Boop FA, Davidoff AM, Pfeffer LM (2017) The effects of type I interferon on glioblastoma cancer stem cells. Biochem Biophys Res Commun 491(2):343–348. https://doi.org/10.1016/j.bbrc.2017.07.098
Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, Yoshida J (2005) IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65(17):7573–7579. https://doi.org/10.1158/0008-5472.CAN-05-0036
De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, Mazzoleni S, Moi D, Venneri MA, Indraccolo S, Falini A, Guidotti LG, Galli R, Naldini L (2008) Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14(4):299–311. https://doi.org/10.1016/j.ccr.2008.09.004
Shen F, Guo Q, Hu Q, Zeng A, Wu W, Yan W, You Y (2018) RelB, a good prognosis predictor, links cell-cycle and migration to glioma tumorigenesis. Oncol Lett 15(4):4404–4410. https://doi.org/10.3892/ol.2018.7894
Kina I, Sultuybek GK, Soydas T, Yenmis G, Biceroglu H, Dirican A, Uzan M, Ulutin T (2019) Variations in Toll-like receptor and nuclear factor-kappa B genes and the risk of glioma. Br J Neurosurg 33(2):165–170. https://doi.org/10.1080/02688697.2018.1540764
Akman L, Erbas O, Akdemir A, Yavasoglu A, Taskiran D, Kazandi M (2015) Levetiracetam ameliorates ovarian function in streptozotocin-induced diabetic rats. Gynecol Endocrinol 31(8):657–662. https://doi.org/10.3109/09513590.2015.1032931